It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption. Objective The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of age-related macular degeneration (AMD). 
Background
Introduction Age-related macular degeneration (AMD) is a disease affecting the central area of the retina (macula). In the early stages of the disease lipid material accumulates in deposits underneath the retinal pigment epithelium. These deposits are known as drusen and can be seen as pale yellow spots on the retina. The pigment of the retinal pigment epithelium may become disturbed with areas of hyperpigmentation and hypopigmentation. In the later stages of the disease the retinal pigment epithelium may atrophy completely. This loss can occur in small focal areas or can be widespread (geographic). In some cases new blood vessels grow under the retinal pigment epithelium and occasionally into the subretinal space (exudative or neovascular AMD). Haemorrhage can occur which often results in increased scarring of the retina. Presentation and epidemiology The early stages of the disease are in general asymptomatic. In the later stages there may be considerable distortion of vision and complete loss of visual function, particularly in the central area of vision. Population-based studies suggest that in people 75 years and older, approximately 30% have early signs of the disease and 7% have late-stage disease . It is the most common cause of blindness and visual impairment in industrialised countries. In the UK, for example, over 30,000 people annually are registered as blind or partially sighted, half of whom have lost their vision due to macular degeneration (Evans 1996) . Treatment options Currently there is no treatment that can restore vision in AMD. Photoreceptors in the retina are subject to oxidative stress throughout life due to combined exposures to light and oxygen. It has been proposed that antioxidants may prevent cellular damage in the retina by limiting the damaging effects of free radicals produced in the process of light absorption (for a review see Christen 1996) . Antioxidant vitamin and mineral supplements are increasingly being marketed for use in age-related eye disease, including AMD.
Description of studies
Finding the trials The original electronic searches identified 577 reports of possible AMD trials of which five reports (four trials) were of antioxidant interventions (AMDSG; Kaiser 1995; Newsome 1988; Stur 1996) . These four trials met the inclusion criteria for this review. Contact with a trial author identified an additional trial of zinc supplementation that has been published in abstract form only (Holz 1993) . In October 2001, the result of the Age-Related Eye Disease Study (AREDS) was published. The reference list of this study report identified that the Vitamin E, Cataract and Age-related Maculopathy Study (VECAT) had been published in abstract form. Searching the reference lists of trial reports located one further possible relevant trial (Vannas 1958) . This study was not included in the review because there was no evidence from the report that the comparison groups (heparin, vitamin A and E, Hydergin therapy and placebo) were randomly allocated or that the allocation was concealed in any way. As the trial was conducted in 1958, no further attempt was made to clarify this. A trial of zinc supplementation (30 mg daily) of people with neovascular AMD in one eye and drusen in the other (n = 170) has been conducted and is as yet unpublished (France 1998) . This trial is listed as 'Awaiting assessment' in this review. Searches were first performed in August 1997 and repeated in October 1998 , December 1999 , September 2000 , November 2001 and May 2005 . Two further trials were identified: Veterans LAST study and a trial published in Chinese which is currently awaiting assessment (Wang 2004) . The searches were updated in January 2006 and August 2007 but no new trials were identified. Summary of included studies Below is a summary of the eight trials included in this review. See 'Characteristics of included studies' for detailed information about the trials. Types of participants The average age of people participating in the trials was 70 years. Slightly more women than men were recruited with the exception of AMDSG and Veterans LAST study where predominantly men were enrolled. In AREDS it was noted that people taking part in the trial were relatively well-nourished compared to the general population. People taking part in the trials were identified by referral from local ophthalmologists (Kaiser 1995; Newsome 1988) , from people attending Department of Veterans Medical Centers (AMDSG; Veterans LAST study), from retinal specialty clinics and general population volunteers (AREDS), from an eye outpatient clinic (Stur 1996; Wang 2004) and from the general population (VECAT). The trials enrolled groups of people with AMD at different stages of the disease: AMDSG and Veterans LAST study considered people with early macular degeneration only; Newsome 1988 examined people with both early and late-stage disease; Stur 1996 enrolled only people with late-stage disease in one eye; Kaiser 1995 recruited only people with geographic AMD. In AREDS participants had a range of disease from mild or borderline features to advanced AMD which was defined as geographic atrophy involving the centre of the macula or features of choroidal neovascularisation. The majority of the participants in VECAT had no or mild age-related maculopathy. Types of intervention Three trials compared zinc sulfate 200 mg daily versus placebo (Holz 1993; Newsome 1988; Stur 1996) . Two trials compared a broad-spectrum antioxidant complex versus placebo (AMDSG -Ocuguard; Kaiser 1995 -Visaline) . VECAT compared vitamin E (500 international units (IU) daily) with placebo. In AREDS a 2x2 factorial design was used. Participants were randomised into four groups: placebo, zinc alone (80 mg daily), antioxidants (vitamin C 500 mg, vitamin E 400 IU and beta-carotene 15 mg) alone and zinc plus antioxidants. In AREDS 67% of participants took other multivitamin supplements to recommended daily allowance levels (Centrum). The Veterans LAST study compared lutein 10 mg daily to lutein plus a broad-spectrum antioxidant (OcuPower). The duration of supplementation in these trials ranged from six months to seven years. The Chinese trial studied zinc oxide (80 mg daily), vitamin C (dose unknown) and vitamin E (dose unknown). Types of outcome measures All the trials used different outcome measures for visual function and progression of disease. AMDSG and Veterans LAST study measured vision using Snellen acuity and converted the score into logMAR units. Newsome 1988 and AREDS used the visual acuity chart developed as part of the Early Treatment of Diabetic Retinopathy Study (ETDRS 1980) . Stur 1996 and VECAT used Bailey-Lovie Charts #4 and #5 (National Vision Research Institute, Australia) . Some studies have presented vision as a continuous outcome (AMDSG ; Kaiser 1995; Stur 1996) , others have used a cut-off of loss of 10 (Newsome 1988) or 15 letters of acuity (AREDS). A loss of 15 letters of acuity is equivalent to a loss of three lines of vision read on the chart and is the same as experiencing a doubling of the visual angle. In most studies disease progression was assessed by grading stereoscopic colour photographs of the retina. Stur 1996 used the Wisconsin Age-Related Maculopathy Grading System (Klein 1991) ; AMDSG used the grading system developed as part of the Chesapeake Bay Waterman Study (Bressler 1989) ; VECAT used the International Grading System (ARMSG 1995); AREDS adapted the Wisconsin system. The Wisconsin, AREDS and International Systems are closely related; the latter was published after the two former systems were in use. All these grading systems involve classification into categories according to the number and type of drusen, pigmentary abnormalities and presence of geographic atrophy or neovascularisation. In AMDSG and Stur 1996 these categories were accorded a score which was analysed as a continuous measure. Newsome 1988 recorded the number of cases of increased drusen, pigment abnormalities and atrophy. Kaiser 1995 did not include any measures of progression of AMD. AREDS reported data for three categories of participant: (i) mild or borderline AMD features (n = 1063); (ii) AMD but not advanced AMD (n = 1621) and (iii) advanced AMD or reduced visual acuity due to AMD in one eye (n = 956). Advanced AMD was defined as signs of geographic atrophy involving the centre of the macula or signs of choroidal neovascularisation (defined as the presence of fluid, blood or fibrovascular tissue under the retina or retinal pigment epithelium). The study followed up 90% of the cohort by the end of five years; the mean follow-up time was 6.3 years. On the basis of having missed the last two consecutive study visits, 2.4% were defined as lost to follow up. In the borderline AMD group, 1.3% progressed to advanced AMD by five years (15 AMD events); in the advanced AMD category, 43% progressed to advanced AMD (in the other eye) by five years and 18% progressed in the intermediate group. At five year follow up 71% of participants were taking 75% or more of their tablets. The investigators found that individuals with outcomes such as signs of advanced AMD and visual acuity loss of 15 or more letters could recover later on. Approximately 8% of the identified cases of advanced AMD, based on central grading of colour stereo photographs, apparently recovered as the AMD lesions were not seen on subsequent yearly photographs. The report did not distinguish between grading errors and verified disappearance of lesion. For this reason they used repeated measures logistic regression which counts each event but also allows for the fact that the event could 'recover'. Outcomes were not clearly defined for the Chinese trials (Wang 2004) .
Results
provides more information on the outcomes and follow-up times relating to the data included in these analyses.
Comparison 01: multivitamin supplement versus placebo do-0177.pdf http://www.medicinacomplementar.com.br/convertido/do-0177.htm
These analyses were restricted to trials of multivitamin and mineral supplements: AREDS (vitamins C, E, beta-carotene and zinc), AMDSG (Ocuguard), Kaiser 1995 (Visaline) Stur 1996) . In addition there is one unpublished study for which we have no data (France 1998). Outcome 1, distance visual acuity: loss of three or more lines Two trials reported visual acuity data in this format (AREDS; Newsome 1988). The pooled analyses include a total of 984 people randomised to zinc supplementation and 974 to placebo. The trials were consistent I² = 0%. There was a modest beneficial effect of treatment on visual acuity (pooled OR 0.81, 95% CI 0.66 to 0.99). (Analysis 02.01) Outcome 2 distance visual acuity: mean Two trials provided data for this outcome (Newsome 1988; Stur 1996) . A total of 77 people were randomised to zinc supplementation and 78 to placebo in these two trials which had a maximum treatment and follow-up duration of 24 months. The results of these trials were less consistent, I2 = 56.6% (Analysis 02.02). Newsome 1988 found that there was more visual acuity loss in the control group than the treatment group although this did not reach statistical significance. Stur 1996 found little difference between the two groups with respect to mean visual acuity at the end of the study. In Stur 1996 the primary outcome was incidence of choroidal neovascularisation (CNV) in all patients. During the treatment period, a CNV developed in the study eye in 14 patients (nine in the treatment group, five in the placebo group). People who experienced a CNV were not included in the analyses of visual acuity. Outcome 3 progression AMD: dichotomous Three trials provided data for this outcome (AREDS; Holz 1993; Stur 1996) . A total of 969 people were randomised to zinc supplementation and 974 to placebo. Overall, there was a modest benefit of treatment (Analysis 02.03). The pooled OR was 0.73 (95% CI 0.58 to 0.93). Stur 1996 had quite different results to the other two trials. Over the treatment period, nine people experienced a CNV in the study eye in the zinc group compared to five people in the placebo group. This may have been a chance finding, however. The OR for that trial (2.31) had wide confidence intervals and the results are therefore also consistent with a protective effect of treatment (95% CI 0.58 to 9.26). Overall, the I2 value was 29.0%. Holz 1993 has been published in abstract form only so we have little information about this trial. Comparison 04: lutein or zeaxanthin versus placebo Outcome 1 distance visual acuity: mean There has only been one trial published to date comparing supplementation with lutein versus placebo (Veterans LAST study). The trial was small with a total of 25 people randomised to lutein supplementation and 27 to placebo; the treatment duration and follow up was 12 months. The only outcome of relevance to this review, for which data could be extracted, was mean visual acuity at the end of the study. This showed little evidence of any effect of treatment: mean difference logMAR acuity 0.04 (95% CI -0.15 to 0.23). The power of the study was low.
Comparison 05: any multivitamin or single component antioxidant supplement versus placebo Outcome 1, distance visual acuity: loss of 15 or more letters Three trials contributed to this analysis (AREDS; Newsome 1988; VECAT) . The trials were reasonably consistent (I2 = 27.7%) (Analysis 03.01). Overall there was a small beneficial effect of supplementation (pooled OR fixed-effect model 0.81, 95% CI 0.67 to 0.98, P = 0.03). A random-effects model gave a different result (pooled OR 0.83, 95% CI 0.63 to 1.09, P = 0.18). The difference in these two models reflects the difference in weighting given to the largest trial (AREDS) -75% in the fixed-effect model versus 63% in the random-effects model. Outcome 2, distance visual acuity: mean Not all trials reported visual acuity data in a dichotomous format. Some trials reported average distance visual acuity at the end of the follow-up period or the mean change in visual acuity. Five trials contributed to this analysis (AMDSG; Kaiser 1995; Newsome 1988; Stur 1996 ; Veterans LAST study). A total of 146 people were randomised to treatment and 140 to control. The results of the different studies were consistent (I2 = 0%) (Analysis 03.02).
There was little evidence of any benefit of treatment. The pooled standardised mean difference (random-effects model) was 0.02 (95% CI -0.21 to 0.26). A fixed-effect model gave identical results. Duration of treatment and follow up in these trials ranged from 6 to 24 months. Outcome 3, progression AMD: dichotomous Data on the progression of AMD was not reported or was reported in such a way as to make it difficult to extract data for this review in three studies (Kaiser 1995; Newsome 1988 ; Veterans LAST study). Four trials contributed data on the progression of AMD as a dichotomous outcome (AREDS; Holz 1993; Stur 1996; VECAT) (figure 0303). The results of the trials were inconsistent (I2 = 64.2%) with the ORs for the individual studies ranging from 0.50 to 2.31. Estimating a pooled OR, therefore, was not of value in this case. Moreover, these trials were quite different in terms of the interventions studied, follow-up period and method of evaluating progression of AMD. (See). Outcome 4, progression AMD: continuous One study (AMDSG) reported data on the progression of AMD in a continuous format. There was little evidence for any benefit of treatment (mean difference -0.06, 95% CI -0.62 to 0.50). The number of participants in this analysis was small with 35 in the treatment group and 24 in the control group. There was limited information from the Chinese trial (Wang 2004 ), particularly about the definitions of the outcome. However, the do-0177.pdf http://www.medicinacomplementar.com.br/convertido/do-0177.htm authors reported that supplementation with zinc, vitamin E and vitamin C over 24 months had no effect on the progression of early ARM (chi-squared test P > 0.05) but had a beneficial effect on the progression of the disease in people with advanced AMD. 12/124 people receiving supplements who had large drusen, geographic atrophy or neovascularisation in one eye progressed to "advanced AMD" (not defined but perhaps comparable to the AREDS definitions) compared to 36/124 in the placebo group (chi-squared P < 0.05). Quality of life None of the trials have reported on quality of life. Adverse effects The main reported adverse effect leading to withdrawal from the studies was gastrointestinal symptoms. Of 286 people randomised into trials of zinc sulfate supplementation compared to placebo, 5/146 zinc-treated people withdrew due to gastrointestinal symptoms compared to 2/140 controls. No-one developed copper-deficiency anaemia. In AMDSG one person developed an 'allergic reaction' although it was not clear whether or not this was related to the treatment. AREDS considered a number of safety outcomes. They conducted over 100 comparisons of zinc versus no zinc and antioxidants versus no antioxidants. Participants in the antioxidant arms more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). Participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004), however, serum haematocrit levels were the same. They found that participants taking zinc had a lower mortality. Later follow-up of the cohort of people taking part in the AREDS study found that there was a significant increase in hospital admissions due to genitourinary diseases in people taking zinc supplements (11.1% versus 7.6% P = 0.0003) .
Discussion
The trials contributing to this review fall into two categories. There are two large trials with reasonably long treatment duration and follow up of four to six years (AREDS; VECAT). The other six trials are smaller (ranging from 20 to 151 participants) and have shorter duration of treatment and follow up (6 to 24 months). The large trials provide reasonably clear answers to different questions. The AREDS trial provides evidence that long-term supplementation with vitamins C, E, beta-carotene and zinc, in people with AMD, reduced the risk of progression of the disease and visual acuity loss. The overall benefit is modest with a risk reduction in the order of 20% to 25%. However, given that treatment options for AMD are limited, and vision loss is rarely recovered, this is of interest to people with AMD. The VECAT study suggests that the general population should not take vitamin E with a view to preventing the incidence or progression of AMD. However, the study was underpowered to answer the question as to whether people with signs of AMD, such as those participating in the AREDS study, should take vitamin E. Currently VECAT is the only published trial on vitamin E supplementation and AMD. The other trials of multivitamin preparations, Ocuguard (AMDSG), Ocupower (Veterans LAST study) and Visaline (Kaiser 1995) are too small to provide evidence either way. Pooling results, where possible, did not provide evidence of any benefit of supplementation. However, these trials were of relatively short duration. A total of five trials investigated zinc supplementation (AREDS; France 1998; Holz 1993; Newsome 1988; Stur 1996) . The AREDS study indicated that the beneficial effect of zinc supplementation was of a similar order to that of vitamin supplementation. The other trials provide more conflicting evidence. Newsome 1988 found a reduction in the risk of visual acuity loss with supplementation over 12 to 24 months. However, Stur 1996 found no effect of treatment. Unfortunately Stur 1996, which was planned to recruit 500 participants, was terminated early because the results of the first 40 patients at 24 months indicated no benefit of treatment. The other two trials of zinc supplementation are as yet unpublished, although limited results from Holz 1993 were published in abstract form and are included here. The trialists have been contacted with a view to including unpublished data in future versions of this review. The main evidence that antioxidant vitamin and mineral supplementation is of benefit comes from the AREDS trial. As AREDS is a large well-conducted randomised study, potential biases will have been minimised. The only area where bias may have been introduced is if there were different systemic effects of the antioxidant and zinc supplementation (for example, yellowing of skin or difficulty swallowing tablets) which led the participants to guess which group they were in or alternatively, the retinal fundus photographs might have been different in some way such that the graders response was affected by treatment group. There is little evidence that this was a problem in the study. AREDS was the only study to examine in detail the question of safety. They found little evidence of harm, however, recent follow-up of the cohort suggests an increased risk of hospital admission due to genitourinary complications in people taking the zinc supplements. The safety of some of the components of the AREDS formulation have been questioned in other studies. Two large randomised controlled trials have indicated that smokers who take beta-carotene may be at increased risk of developing lung cancer (ATBC; Omenn 1996) . The Heart Outcomes Prevention Evaluation (HOPE) Study found that, among people with vascular disease or diabetes, vitamin E supplementation was associated with a higher risk of heart failure (Hope 2005).
Reviewers' conclusions Implications for practice
People with AMD may experience modest delay in progression of the disease with antioxidant vitamin and mineral supplementation. This finding is drawn from one large trial conducted in a relatively well-nourished American population. Until it is replicated by other large-scale trials in other populations we will not know whether these findings can be applied more generally. Antioxidant vitamin and mineral supplements are readily available for purchase without prescription in many countries. The decision as to whether to take these supplements is at the discretion of the person with AMD. The following benefits and harms need to be considered. People with AMD may delay the progression of their condition if they take antioxidant vitamins and zinc at the levels described in this review. Given that there are few other interventions that offer much in the way of disease prevention or cure this is an important consideration. However, harmful effects associated with long-term vitamin supplementation, particularly in smokers and people with vascular disease, cannot be ruled out. A healthy diet with a variety of fresh fruit and vegetables will have many benefits and is unlikely to be harmful. It may be difficult, however, to consume as part of a normal diet the levels of antioxidants and zinc described in the trials included in this review . For example, one orange provides 80 mg of vitamin C; this is a relatively high amount. However, one would need to eat six to seven oranges daily to obtain 500 mg vitamin C. There is currently considerable interest in the potential role of lutein and zeaxanthin supplementation in AMD. This review includes only one small equivocal trial on lutein. Such supplements currently cannot be recommended. Participants Country: USA.Number of participants randomised: 3640.Age: Average age 69 years (range 55 to 80).Sex: 56% female.Inclusion criteria: 20/32 or better in at least one eye; ocular media clear and therefore able to obtain adequate stereoscopic fundus photographs; at least one eye free from eye disease that could complicate assessment of AMD.Exclusion criteria: Illness or disorders that would make long term follow-up or compliance with study protocol unlikely or difficult.
Implications for research

Interventions
Treatment: Antioxidants (500mg vitamin C, 400IU vitamin E, 15mg beta carotene) zinc (80mg of zinc as zinc oxide and 2mg of copper as cupric oxide).Control: Placebo identical in external appearance and similar in internal appearance and taste.Duration: 7 years.
Outcomes
Primary outcomes: (1) progression to advanced AMD and (2) 15 letter or more decrease in visual acuity score. AMD assessed using stereoscopic fundus colour photograph; visual acuity measured using EDTRS logMAR chart. Safety outcomes included: reported adverse events; serum levels of haemoglobin; hospitalisations and mortality.
Notes 2x2 factorial design. 67% participants took additional supplements to RDA levels (Centrum). In 1996 current smokers offered option of discontinuing supplementation; 2% of participants and 18% of smokers did so. A further 2.3% reassigned to no beta-carotene group. Intention to treat analysis maintained. 
